+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 17 Actively Recruiting clinical trials

S

Actively Recruiting

This research aims to evaluate the effectiveness, safety, and tolerability of combining baxdrostat with dapagliflozin compared to dapagliflozin alone in people with chronic kidney disease CKD and high blood pressure. The goal is to reduce the risk of serious kidney problems, heart failure events, or cardiovascular death. This is a phase III, international, multicenter, randomized, double-blind, placebo-controlled, event-driven study focused on treatment outcomes. Participants who do not already use SGLT2 inhibitors will first undergo a 4-week dapagliflozin run-in period. After that, they will be randomly assigned to receive either baxdrostat plus dapagliflozin or placebo plus dapagliflozin. Baxdrostat dosing may start low and be increased if needed. Study visits will occur frequently early on at 2, 4, 8, 16, 34, and 52 weeks post-randomization, then approximately every 4 months. The study will end when a predetermined number of kidney or cardiovascular events occur. During the study, participants will have scheduled visits for assessments including kidney function, heart health, and safety monitoring. If they stop the study treatment early, they will continue on dapagliflozin alone and remain in the trial for follow-up visits. Researchers will measure outcomes such as sustained kidney function decline, kidney failure, heart failure events, cardiovascular death, and all-cause death over up to 37 months. Data collection continues until the study closes, with safety and tolerability closely observed throughout.

Age: 18Years +All GendersPhase 3
771 locations
E

Actively Recruiting

Researchers are evaluating the effectiveness and safety of praliciguat in adults diagnosed with biopsy-confirmed focal segmental glomerulosclerosis FSGS, a kidney disease. This Phase 2, randomized, double-blind, placebo-controlled, multicenter study compares praliciguat to a placebo over an initial 24-week period, followed by an open-label phase where all participants receive praliciguat for another 24 weeks. Those who respond to treatment may join a long-term safety extension study. Participants are randomly assigned to receive either praliciguat or a matching placebo daily during the 24-week double-blind period. After this, all participants take praliciguat daily during the 24-week open-label period. Dose escalation to a target dose occurs during the initial treatment phase. Responders are invited to continue in a long-term safety extension where praliciguat is administered daily. During the study, participants undergo regular assessments including urine protein-to-creatinine ratio UPCR measurements, monitoring for treatment-emergent adverse events, and plasma concentration tests of praliciguat. Safety is closely tracked through reports of adverse events during both treatment periods and the long-term extension. The total participation duration may extend up to more than 48 weeks depending on extension study enrollment.

Age: 18Years +All GendersPhase 2
30 locations
A

Actively Recruiting

Researchers are evaluating whether combining tucatinib with trastuzumab and mFOLFOX6 works better than standard treatments for people with HER2 positive colorectal cancer that has spread or cannot be removed by surgery. This Phase 3 study also aims to learn about the side effects that may occur when taking this combination of drugs. Participants have metastatic or unresectable colorectal cancer and are randomly assigned to different treatment groups. Participants are randomly placed in one of two study groups. One group receives tucatinib taken orally twice daily along with trastuzumab given intravenously every 3 weeks and mFOLFOX6 chemotherapy every 2 weeks. The other group receives standard care, which may be mFOLFOX6 alone or combined with bevacizumab or cetuximab, both given intravenously on different schedules. Tissue samples and biopsies are collected before treatment to confirm HER2 positivity and other markers. During the study, participants will have regular evaluations including imaging scans to measure cancer progression, blood tests, and assessments of side effects and quality of life. Progression-free survival is the primary outcome measured for up to about 3 years, with other outcomes like overall survival and response rate also tracked. Safety monitoring continues for about one year after the last treatment. The study lasts several years, with ongoing follow-up to understand long-term effects and benefits.

Age: 18Years +All GendersPhase 3
366 locations
N

Actively Recruiting

Researchers are evaluating the addition of an immunotherapy drug called durvalumab to the usual chemotherapy treatment for patients with MammaPrint High 2 Risk MP2 stage II-III hormone receptor positive, HER2 negative breast cancer. The trial aims to compare the effectiveness of chemotherapy alone versus chemotherapy combined with durvalumab in preventing cancer recurrence and improving survival. This phase III trial also assesses quality of life and side effects experienced by participants receiving these treatments. Participants first undergo MammaPrint testing on tumor tissue to confirm MP2 status. Those eligible are randomized into two groups one receives standard chemotherapy with paclitaxel, doxorubicin, and cyclophosphamide, while the other receives the same chemotherapy plus durvalumab. Chemotherapy cycles are given intravenously every 14 days for specified numbers of cycles, and durvalumab is administered intravenously during select cycles. Mammography and optional tissue and blood sample collections occur during screening and treatment. Throughout the study, participants are monitored with various assessments including breast cancer event-free survival, pathologic response, relapse-free survival, overall survival, and quality-of-life measures such as fatigue and physical health. Blood samples and tumor tissues may be collected for future research. After completing treatment, participants are followed for up to 10 years to track long-term outcomes and safety.

Age: 18Years +All GendersPhase 3
564 locations
R

Actively Recruiting

Researchers are evaluating the addition of cemiplimab, an immunotherapy drug that blocks the PD-1 pathway to help the immune system attack tumor cells, to the usual treatment of docetaxel and ramucirumab for patients with stage IV or recurrent non-small cell lung cancer NSCLC who have previously been treated with platinum chemotherapy and immunotherapy. This phase IIIII randomized trial aims to compare overall survival and other outcomes between the two treatment approaches, including progression-free survival, response rates, and safety. Participants are randomly assigned to one of two groups. One group receives dexamethasone orally, ramucirumab intravenously, and docetaxel intravenously every 21 days. The other group receives the same treatment plus cemiplimab intravenously every 21 days. Treatment cycles continue as long as there is no disease progression or unacceptable side effects. Throughout the study, participants have blood samples collected and undergo CT or MRI scans to monitor disease status. During the study, participants will have regular assessments including tumor imaging and blood tests to track treatment effects and side effects. After completing treatment, participants are followed every 3 to 6 months for up to 3 years to monitor overall survival and disease progression. The study also collects samples for future research on tumor DNA. Total participation can last several years including treatment and follow-up periods.

Age: 18Years +All GendersPhase 2Phase 3
413 locations
E

Actively Recruiting

Researchers are evaluating how to best recommend chemotherapy for patients with colon cancer based on the presence or absence of circulating tumor DNA ctDNA after surgery. This Phase IIIII trial aims to determine if ctDNA can be used to better identify patients who need adjuvant chemotherapy and to assess optimal chemotherapy regimens for those with detectable ctDNA, as current biomarkers have not been prospectively validated. Participants are assigned to different groups based on their ctDNA status after surgery. Those without detectable ctDNA may undergo serial ctDNA monitoring without treatment or receive shorter chemotherapy regimens. Patients with detectable ctDNA receive more intensive chemotherapy options, including combinations of oxaliplatin, leucovorin, 5-fluorouracil, irinotecan, or capecitabine, administered intravenously or orally over cycles lasting several weeks. The study includes randomization and uses the Signatera test for central ctDNA detection. During the study, participants will undergo regular blood tests for ctDNA status, imaging scans, and clinical assessments. Researchers will track ctDNA positivity over up to 3 years and disease-free survival over up to 5 years. Other measures include overall survival, recurrence rates, and chemotherapy compliance. The total study duration may extend several years with ongoing monitoring to evaluate safety and treatment outcomes.

Age: 18Years +All GendersPhase 2Phase 3
1085 locations
P

Actively Recruiting

Researchers are evaluating combinations of targeted drugs in people with advanced non-small cell lung cancer that has spread and shows specific changes in the EGFR and MET genes. This phase II Lung-MAP trial focuses on patients whose cancer has progressed after treatment with osimertinib and aims to compare the effectiveness of combining capmatinib, osimertinib, and ramucirumab. The study also investigates safety, response rates, and survival outcomes while collecting biological samples for further analysis. Participants are randomly assigned to one of two groups. One group receives capmatinib and osimertinib as oral medications plus ramucirumab given intravenously, while the other group receives only capmatinib and osimertinib orally. During the trial, patients undergo regular CT or MRI scans and blood sample collections to monitor their disease and treatment effects. The study includes detailed assessments of tumor responses and side effects over time. Throughout the trial, participants will have scans and blood tests at scheduled intervals to assess disease progression and treatment impact. Researchers will monitor progression-free survival as the main outcome, along with response duration and toxicity. Blood samples are also collected to study circulating tumor DNA. The study continues up to three years, with ongoing safety and efficacy evaluations. Participants must meet specific health criteria and provide informed consent before joining.

Age: 18Years +All GendersPhase 2
454 locations
P

Actively Recruiting

Researchers are evaluating whether adding surgery to remove the kidney cytoreductive nephrectomy improves overall survival compared to immunotherapy-based drug combinations alone in patients with metastatic kidney cancer. This phase III trial focuses on patients with newly diagnosed metastatic renal cell carcinoma, exploring the effects of combining surgery with immunotherapies such as nivolumab, ipilimumab, pembrolizumab, and avelumab, along with axitinib, which may help slow tumor growth. Participants initially receive one of three standard immune checkpoint inhibitor-based regimens before randomization. After 10 to 14 weeks, eligible patients are randomly assigned to continue systemic immunotherapy with or without surgery to remove the kidney. Surgery may be performed within 8 weeks after randomization and can be done using laparoscopic, open, or robotic methods. Immunotherapies continue alongside axitinib unless surgery is planned, in which case axitinib is paused at least 24 hours before surgery. Throughout the study, participants undergo scans, physical exams, and laboratory tests to monitor tumor response and overall health. After treatment, patients are followed up every 3 months for the first year, then every 6 months for up to 3 years, and annually up to 7 years from randomization. The main measurement is overall survival, with additional assessments including tumor response, progression-free survival, treatment complications, and changes in tumor size at week 12. Specimens may be collected for future research.

Age: 18Years +All GendersPhase 3
387 locations
V

Actively Recruiting

Researchers are evaluating whether a virtual exercise program can be effectively delivered to cancer patients receiving chemotherapy. The study aims to help patients maintain strength and reduce fatigue caused by cancer treatments, which can interfere with daily activities and work. This supportive care trial focuses on patients with various localized malignant solid tumors undergoing curative-intent chemotherapy. Participants follow a supervised exercise program via telehealth video calls that include resistance and aerobic exercises. They complete supervised aerobic and resistance sessions twice a week and additional unsupervised aerobic exercises weekly, continuing until the end of their chemotherapy or up to six months. Patients receive exercise equipment such as a stationary bike, dumbbells, resistance bands, and wear an accelerometer to monitor activity. During the study, researchers monitor exercise session completion, patient retention, and physical function changes using tests like the 6 Minute Walk Test and grip strength. Patients also complete questionnaires and interviews about their physical activity and quality of life. Follow-up assessments occur four weeks and three months after the intervention, with total participation lasting up to six months or until chemotherapy completion.

Age: 18Years +All GendersPhase Not Applicable
30 locations
S

Actively Recruiting

Researchers are evaluating the effects of a new biophoton therapy on patients with brain disorders such as Alzheimers disease, dementia, stroke, traumatic brain injury, and Parkinsons disease. This randomized, triple-blinded, placebo-controlled clinical study aims to confirm previous findings that the biophoton therapy is safe and effective in treating these conditions. Approximately 80 participants with brain disorders will take part in the study at the Tesla MedBed Center. Participants will stay in a hotel-like research center for either 4 weeks or 6 weeks, depending on group assignment. For the first 2 weeks, the study is triple-blinded participants will use either 14 active biophoton generator devices placed under the bed and two on each side of the head, or 14 placebo devices arranged in the same way. All participants will use their assigned devices for at least 8 hours each night during sleep. After 2 weeks, those initially in the placebo group will switch to the active treatment for 4 more weeks, while those in the treatment group will continue for 2 more weeks. Throughout the study, participants will complete quality of life and cognitive questionnaires, undergo neurologic exams, and have tests including Bio-well energy, electroencephalography EEG, blood flow, and brain biophoton measurements at baseline, 2 weeks, and 4 weeks. The primary outcomes measured are overall life quality and cognitive capacity changes related to the biophoton therapy. Secondary outcomes include neurological function, brain activity, brain bio-energy, and blood circulation. The study includes close monitoring with quadruple masking to ensure unbiased results.

Age: 18Years +All GendersPhase Not Applicable
1 location

1-10 of 17

1